ImmunoGen Shares Collapse After Huge Miss on Profits, Revenues
Cancer drug developer ImmunoGen posted sharply lower profits and revenues than analysts were expecting. The stock is taking a beating as a result.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 153
Intellia Therapeutics Gears Up for Secondary Offering
Intellia Therapeutics saw its shares take a dip on Thursday after the firm announced the pricing of its secondary offering.
Teva Earnings Send Shares to New Low Not Seen in Over a Decade
These quarterly numbers are another black eye for Teva Pharmaceutical, sending shares to a low not seen since 2002.
Can This FDA Approval Keep Lifting Geron?
Geron is one of the few biopharma winners on Tuesday, with the health care sector in general pushing slightly lower on the day.
Pfizer Earnings Not Enough for Investors
When Pfizer released its third-quarter earnings report before the markets opened on Tuesday, the results and guidance lived up to what analysts expected but weren't enough to placate investors.
Why Neos Therapeutics Is Holding Out Against PDL BioPharma
In a decisive move, the Neos Therapeutics board of directors unanimously struck down an acquisition proposal from PDL BioPharma.
What to Expect When Pfizer Reports Earnings
Pfizer is scheduled to release its third-quarter financial results before the markets open on Tuesday.
Why Novartis Is Moving to Acquire Advanced Accelerator Applications
Advanced Accelerator Applications shares made a run early on Monday after it came public that Novartis plans to buy the company.
Endo International Wins Big on Preliminary Results
Endo International saw its shares make a solid gain to start off the week after the firm announced preliminary financial results for its third quarter.
Top Biopharma Events Coming by the End of 2017
24/7 Wall St. has collected a few pharma and biotech catalysts that are coming up on the calendar in November and December.
Despite Poor Earnings Reaction, Analysts Still See Upside for Gilead
Out of all the biotechs that reported earnings last week, Gilead Sciences seems to be the one that hasn’t been taking its medicine in 2017.
Why AbbVie Won Big in Q3, and Can Keep Winning
AbbVie reported better-than-expected third-quarter before the markets opened on Friday due to strong sales of Humira and Imbruvica.
Merck Earnings Fall Short Despite Incredible Keytruda Sales
Pharma giant Merck reported mixed third-quarter financial results before the markets opened on Friday.
Gilead Earnings Bring Mixed Results
Gilead Corporation (NASDAQ: GILD) has joined other biotech giants in releasing its earnings for the third quarter of 2017. The company’s market cap was last seen at $101 billion before earnings, and that was…
National Vision Enters the Market With a Bang
National Vision Holdings entered the market with a bang Thursday morning. The company priced its shares above the expected range.